Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2018 | Which NSCLC patients should receive chemotherapy and anti-angiogenics?

Marina Garassino • 11 Apr 2018
ELCC 2018
Lung Cancer Non-Small Cell Lung Cancer Bevacizumab Docetaxel Nintedanib Ramucirumab

Anti-angiogenic therapy has proven to be useful tool for the treatment of non-small cell lung cancer (NSCLC) in the frontline setting. Excitingly, there are now anti-angiogenic agents that can be used in the second-line setting, including ramucirumab and nintedanib, as described here by Marina Garassino, MD, of the Istituto Nazionale dei Tumori, Milan, Italy. This video was recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.

More from Marina Garassino

3:25
PACIFIC 6: durvalumab after sCRT in patients with NSCLC
Marina Garassino • 18 Mar 2021
4:28
Combining chemotherapy and immunotherapy: key trials in lung cancer
Marina Garassino • 18 Mar 2021
3:04
TERAVOLT: outcomes for patients with COVID-19 and lung cancer
Marina Garassino • 18 Mar 2021
1:43
Novel targets for NSCLC
Marina Garassino • 18 Mar 2021

Related Videos

2:38
Phase I trial of binimetinib and pembrolizumab in NSCLC
Natasha Leighl • 17 Apr 2024
2:43
CHRYSALIS: amivantamab in wild-type, pre-treated NSCLC
Natasha Leighl • 17 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
The content of VJOncology is intended for healthcare professionals